🚨 Apixaban shows a significantly lower bleeding risk than rivaroxaban — what does the evidence say?
In the management of acute venous thromboembolism (VTE), selecting the right anticoagulant is critical — especially when balancing efficacy and safety.
A large randomized trial involving 2760 patients compared Apixaban and Rivaroxaban over a 3-month treatment period.
📊 Key Findings:
• Clinically relevant bleeding occurred in:
✔ 3.3% with apixaban
✔ 7.1% with rivaroxaban
➡ This reflects a 54% lower risk of bleeding with apixaban (P < 0.001)
• Death from any cause was low in both groups:
• 0.1% (apixaban) vs 0.3% (rivaroxaban)
• Serious adverse events were comparable between the two treatments.
💡 Clinical Takeaway:
This study highlights that apixaban may offer a safer bleeding profile compared to rivaroxaban in patients with acute VTE, while maintaining similar overall outcomes.
🔍 However, individual patient factors and clinical judgment remain essential in anticoagulant selection.
💬 Which anticoagulant do you prefer in your practice — and why?
Source : CLICK HERE
Comments
Post a Comment